Daré Bioscience Inc (NASDAQ: DARE) received a Buy rating and a $3 price target from Maxim Group analyst Caroline Palomeque today. The company’s shares closed yesterday at $0.99, close to its 52-week low of $0.74.
“We are initiating coverage of Daré Bioscience, Inc. (DARE) with a Buy rating and $3 price target. Daré is developing two lead assets in women’s health; Ovaprene non-hormonal vaginal ring for contraception and SST-6007 topical Viagra for female sexual arousal disorder (FSAD).”
According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.7% and a 34.0% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
Daré Bioscience Inc has an analyst consensus of Hold.
Based on Daré Bioscience Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.58 million. In comparison, last year the company had a GAAP net loss of $4.14 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Daré Bioscience, Inc. operates as a healthcare company. It engages in the development and commercialization of pharmaceutical products in women’s reproductive health. Its products inclide Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in La Jolla, CA.